Edgestream Partners, L.P. Biogen Inc. Transaction History

Edgestream Partners, L.P.

$2.05 Billion
Q2 2024

A detailed history of Edgestream Partners, L.P. transactions in Biogen Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 929 shares of BIIB stock, worth $172,496. This represents 0.01% of its overall portfolio holdings.

Number of Shares

929

Previous 1,650 43.7%

Holding current value

$172,496

Previous $355,000 39.44%

% of portfolio

0.01%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$190.52 - $236.72 $137,364 - $170,675	-721 Reduced 43.7%	929 $215,000
Q1 2024 May 10, 2024	BUY	$212.02 - $267.71 $349,833 - $441,721	1,650 New	1,650 $355,000
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $1.11 Million - $1.25 Million	4,386 New	4,386 $1.13 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $1.2 Million - $1.42 Million	-6,375 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $6.44 Million - $8.11 Million	-33,212 Reduced 83.9%	6,375 $1.34 Million
Q4 2021 Feb 15, 2022	BUY	$223.92 - $287.77 $5.01 Million - $6.44 Million	22,373 Added 129.97%	39,587 $9.5 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $3.76 Million - $4.91 Million	13,291 Added 338.8%	17,214 $4.87 Million
Q2 2021 Aug 10, 2021	BUY	$259.0 - $414.71 $1.02 Million - $1.63 Million	3,923 New	3,923 $1.36 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $294,931 - $373,562	-1,059 Closed	0 $0
Q3 2018 Nov 07, 2018	SELL	$293.51 - $383.83 $1.59 Million - $2.08 Million	-5,409 Reduced 83.63%	1,059 $374,000
Q2 2018 Aug 09, 2018	SELL	$257.52 - $306.91 $824,579 - $982,725	-3,202 Reduced 33.11%	6,468 $1.88 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $2.52 Million - $3.56 Million	9,670 New	9,670 $2.65 Million

Others Institutions Holding BIIB

# of Institutions

1,049

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $26.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.

Account

Edgestream Partners, L.P. Biogen Inc. Transaction History